Metabolic syndrome in polycystic ovary syndrome: a review
Keywords:Polycystic ovary syndrome, Metabolic syndrome, Insulin resistance, Dyslipidaemia, Hyperandrogenism
Polycystic ovary syndrome is one of the most common endocrine abnormalities in women. It affects both reproductive life and overall health of the women including metabolic abnormalities. A multidisciplinary approach is needed in those with metabolic variations to prevent them from the long-term complications like cardiovascular diseases and diabetes mellitus. The objective of this article is to review the association between PCOS and metabolic syndrome.
Trikudanathan S. Polycystic ovarian syndrome. Med Clin North Am. 2015;99(1):221-35.
Rasquin Leon LI, Mayrin JV. Polycystic Ovarian Disease. Treasure Island (FL): StatPearls Publishing; 2020.
Ndefo UA, Eaton A, Green MR. Polycystic ovary syndrome: a review of treatment options with a focus on pharmacological approaches. Pharmac Therapeut. 2013;38(6):336.
Ding DC, Chen W, Wang JH, Lin SZ. Association between polycystic ovarian syndrome and endometrial, ovarian, and breast cancer: A population-based cohort study in Taiwan. Medicine. 2018;97(39).
Pelusi B, Gambineri A, Pasquali R. Type 2 diabetes and the polycystic ovary syndrome. Minerva Ginecol. 2004;56(1):41-51.
Rojas J, Chávez M, Olivar L, Rojas M, Morillo J, Mejías J, Calvo M, Bermúdez V. Polycystic ovary syndrome, insulin resistance, and obesity: navigating the pathophysiologic labyrinth. Int J Reproduct Medic. 2014;2014.
Chandrasekaran S, Sagili H. Metabolic syndrome in women with polycystic ovary syndrome. Obstet Gynaecolo. 2018;20(4):245-52
Glueck CJ, Goldenberg N. Characteristics of obesity in polycystic ovary syndrome: etiology, treatment, and genetics. Metabolism. 2019;92:108-20.
Wang ET, Calderon-Margalit R, Cedars MI, Daviglus ML, Merkin SS, Schreiner PJ, Sternfeld B, Wellons M, Schwartz SM, Lewis CE, Williams OD. Polycystic ovary syndrome and risk for long-term diabetes and dyslipidemia. Obstet Gynecol. 2011;117(1):6.
Swarup S, Goyal A, Grigorova Y, et al. Metabolic Syndrome. In: StatPearls. Treasure Island: StatPearls Publishing; 2020.
Takamiya T, Zaky WR, Edmundowics D, Kadowaki T, Ueshima H, Kuller LH, et al. World Health Organization-defined metabolic syndrome is a better predictor of coronary calcium than the adult treatment panel III criteria in American men aged 40–49 years. Diabet Car. 2004;27(12):2977-9.
Saif-Ali R, Kamaruddin NA, Molham AH, Al-Dubai SA, Ngah WZ. Relationship of metabolic syndrome defined by IDF or revised NCEP ATP III with glycemic control among Malaysians with Type 2 Diabetes. Diabetol Metabol Syndro. 2020;12(1):1-7.
Rajska A, Buszewska-Forajta M, Rachoń D, Markuszewski MJ. Metabolomic insight into polycystic ovary syndrome—An overview. Int J Molecul Sci. 2020;21(14):4853.
Fenwick PH, Jeejeebhoy K, Dhaliwal R, Royall D, Brauer P, Tremblay A, Klein D, Mutch DM. Lifestyle genomics and the metabolic syndrome: A review of genetic variants that influence response to diet and exercise interventions. Crit Rev Food Sci Nutr. 2019;59(13):2028-39.
Khan Y, Lalchandani A, Gupta AC, Khadanga S, Kumar S. Prevalence of metabolic syndrome crossing 40% in Northern India: Time to act fast before it runs out of proportions. J Fam Medicine Prim Care. 2018;7(1):118.
De Meyts P. The insulin receptor and its signal transduction network. InEndotext. 2016.
Foroozanfard F, Moosavi SG, Mansouri F, Bazarganipour F. Obstetric and neonatal outcome in PCOS with gestational diabetes mellitus. J Fam Reproduct Heal. 2014;8(1):7.
Kim JJ, Choi YM. Dyslipidemia in women with polycystic ovary syndrome. Obstet Gynecol Sci. 2013;56(3):137-42.
Amiri M, Tehrani FR, Behboudi-Gandevani S, Bidhendi-Yarandi R, Carmina E. Risk of hypertension in women with polycystic ovary syndrome: a systematic review, meta-analysis and meta-regression. Reproduct Biol Endocrinol. 2020;18(1):1-5.
Ożegowska K, Bogacz A, Bartkowiak‑Wieczorek J, Seremak‑Mrozikiewicz A, Pawelczyk L. Association between the angiotensin converting enzyme gene insertion/deletion polymorphism and metabolic disturbances in women with polycystic ovary syndrome. Molecul Medic Rep. 2016;14(6):5401-7.
De Groot PC, Dekkers OM, Romijn JA, Dieben SW, Helmerhorst FM. PCOS, coronary heart disease, stroke and the influence of obesity: a systematic review and meta-analysis. Hum Reproduct Update. 2011;17(4):495-500.
Ohashi K, Ouchi N, Matsuzawa Y. Adiponectin and hypertension. Am J Hypertens. 2011;24(3):263-9.
Sasaki A, Emi Y, Matsuda M, Kamada Y, Chekir C, Hiramatsu Y, Nakatsuka M. Increased arterial stiffness in mildly‐hypertensive women with polycystic ovary syndrome. J Obstet Gynaecol Res. 2011;37(5):402-11.
Mannerås-Holm L, Baghaei F, Holm G, Janson PO, Ohlsson C, Lönn M, Stener-Victorin E. Coagulation and fibrinolytic disturbances in women with polycystic ovary syndrome. J Clinic Endocrinol Metabol. 2011;96(4):1068-76.
Studen KB, Pfeifer M. Cardiometabolic risk in polycystic ovary syndrome. Endocr Connect. 2018;7(7):R238-51.
Dalle Grave R, Calugi S, Centis E, Marzocchi R, El Ghoch M, Marchesini G. Lifestyle modification in the management of the metabolic syndrome: achievements and challenges. Diabet Metabol Syndrom Obes. 2010;3:373.
Marvasti TB, Adeli KH. Pharmacological management of metabolic syndrome and its lipid complications. J Pharmaceut Sci. 2010;18(3):146.
Srinivasan K. Dietary spices as beneficial modulators of lipid profile in conditions of metabolic disorders and diseases. Food Funct. 2013;4(4):503-21.